Characterization of the sensitivity and specificity of different IL17A antibodies will have to be done to reduce the potential cross-reactivity with other IL-17 isoforms, since different IL-17 isoforms can activate different signaling pathways even within the same cancer type. This evidence concerns the gene IL17A and cancer.